Any perceived energy increase results indirectly from improved blood sugar control, weight loss, and resolution of obesity-related symptoms rather than pharmacological stimulation
White, faded, or off-color signals indicate missing or degraded copper coordination
Not every drug is right for every person, so its essential to consider your options with a clinician
Most incretin-based therapies drive impressive fat loss, but at a cost: significant lean mass depletion worse metabolic health higher long-term risk, especially in Diabetes This graphic highlights a two-pronged approach: Semaglutide reduces appetite & fat mass Bimagrumab blocks ActRIIA/B signalling, preventing muscle atrophy Clinical data (BELIEVE trial) shows that combining the two: enhances fat loss preserves or increases lean mass improves overall body composition, not just the number on the scale In a season where weight gain is almost guaranteed, the future of obesity treatment isnt eat less and lose everything. Its lose fat while building muscle
Semaglutide: The Appetite Whisperer What it targets: GLP-1 Think of GLP-1 as your bodys Im full hormone
1 and 4)
